文献速递乳腺癌支持与姑息治疗

血清检测他莫昔芬不依从与乳腺癌复发风险

Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk.
PubMed 文献 · J Clin Oncol · 2020-06-22

在1177例绝经前乳腺癌患者中,处方的1年后血清他莫昔芬浓度<60 ng/mL定义生化不依从,发生率为16.0%,而患者自报不依从率仅12.3%。

要点

  • 血清他莫昔芬浓度可客观识别不依从,自报会低估。
  • 生化不依从与远处复发或死亡风险升高相关。
  • 治疗药物监测或有助于及时干预依从性。

核心结论

  • 血清他莫昔芬浓度<60 ng/mL定义的生化不依从与更短远处无病生存期独立相关。

研究设计与样本

  • 前瞻性队列研究(CANTO/NCT01993498)纳入1177例绝经前乳腺癌患者,处方后1年检测血清他莫昔芬浓度并同期自报依从性。

主要发现

  • 16.0%(188例)患者血清他莫昔芬浓度低于60 ng/mL。
  • 患者自报不依从率为12.3%,188例生化不依从者中55%自报依从。
  • 3年无远处复发存活率在不依从组为89.5%,依从组为95.4%。

关键数值与推荐

  • 生化不依从定义:处方后1年血清他莫昔芬浓度<60 ng/mL。

临床怎么用

  • 可考虑用血清他莫昔芬浓度监测辅助识别不依从患者。
  • 对生化不依从者应针对性干预以提高依从性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Nonadherence to long-term treatments is often under-recognized by physicians and there is no gold standard for its assessment. In breast cancer, nonadherence to tamoxifen therapy after surgery constitutes a major obstacle to optimal outcomes. We sought to evaluate the rate of biochemical nonadherence to adjuvant tamoxifen using serum assessment and to examine its effects on short-term, distant disease-free survival (DDFS). PATIENTS AND METHODS: We studied 1,177 premenopausal women enrolled in a large prospective study (CANTO/NCT01993498). Definition of biochemical nonadherence was based on a tamoxifen serum level < 60 ng/mL, assessed 1 year after prescription. Self-reported nonadherence to tamoxifen therapy was collected at the same time through semistructured interviews. Survival analyses were conducted using an inverse probability weighted Cox proportional hazards model, using a propensity score based on age, staging, surgery, chemotherapy, and center size. RESULTS: Serum assessment of tamoxifen identified 16.0% of patients (n = 188) below the set adherence threshold. Patient-reported rate of nonadherence was lower (12.3%). Of 188 patients who did not adhere to the tamoxifen prescription, 55% self-reported adherence to tamoxifen. After a median follow-up of 24.2 months since tamoxifen serum assessment, patients who were biochemically nonadherent had significantly shorter DDFS (for distant recurrence or death, adjusted hazard ratio, 2.31; 95% CI, 1.05 to 5.06; P = .036), with 89.5% of patients alive without distant recurrence at 3 years in the nonadherent cohort versus 95.4% in the adherent cohort. CONCLUSION: Therapeutic drug monitoring may be a useful method to promptly identify patients who do not take adjuvant tamoxifen as prescribed and are at risk for poorer outcomes. Targeted interventions facilitating patient adherence are needed and have the potential to improve short-term breast cancer outcomes.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Pistilli B, Paci A, Ferreira AR, et al. Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk. J Clin Oncol. 2020. PMID: 32568632. doi:10.1200/JCO.19.01758

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。